title: Transforming growth factor alpha induces angiogenesis and neurogenesis following stroke.
abstract: The cytokine transforming growth factor alpha (TGF alpha) has proangiogenic and proneurogenic effects and can potentially reduce infarct volumes. Therefore, we administered TGF alpha or vehicle directly into the area surrounding the infarct in female mice that received gender-mismatched bone marrow transplants from green fluorescent protein (GFP)-expressing males prior to undergoing permanent middle cerebral artery occlusion. Newborn cells were tracked with bromodeoxyuridine (BrdU) labeling and immunohistochemistry at 90 days after stroke onset. We also studied the ingress of bone marrow-derived cells into the ischemic brain to determine whether such cells contribute to angiogenesis or neurogenesis. Infarct volumes were measured at 90 days poststroke. The results show that TGF alpha led to significant increments in the number of newborn neurons and glia in the ischemic hemisphere. TGF alpha also led to significant increments in the number of bone marrow-derived cells entering into the ischemic hemisphere. Most of these cells did not label with BrdU and represented endothelial cells that incorporated into blood vessels in the infarct border zone. Our results also show that infarct size was significantly reduced in animals treated with TGF alpha compared with controls. These results suggest that TGF alpha can induce angiogenesis, neurogenesis and neuroprotection after stroke. At least part of the pro-angiogenic effect appears to be secondary to the incorporation of bone marrow-derived endothelial cells into blood vessels in the infarct border zone.
authors.affiliation: Department of Neurology, Peritz and Chantal Scheinberg Cerebrovascular Research Laboratory, Hebrew University-Hadassah Medical Center, Jerusalem, Israel. leker@cc.huji.ac.il
authors.forename: R R
authors.initials: RR
authors.lastname: Leker
authors.forename: Z E
authors.initials: ZE
authors.lastname: Toth
authors.forename: T
authors.initials: T
authors.lastname: Shahar
authors.forename: R
authors.initials: R
authors.lastname: Cassiani-Ingoni
authors.forename: I
authors.initials: I
authors.lastname: Szalayova
authors.forename: S
authors.initials: S
authors.lastname: Key
authors.forename: A
authors.initials: A
authors.lastname: Bratincsák
authors.forename: E
authors.initials: E
authors.lastname: Mezey
mesh_terms: D000818:Animals; D016026:Bone Marrow Transplantation / Q000379:methods; D002454:Cell Differentiation / Q000502:physiology; D002465:Cell Movement / Q000187:drug effects / Q000502:physiology; D004195:Disease Models, Animal; D042783:Endothelial Cells / Q000187:drug effects / Q000502:physiology / Q000637:transplantation; D005260:Female; D006085:Graft Survival / Q000502:physiology; D049452:Green Fluorescent Proteins; D008297:Male; D051379:Mice; D008810:Mice, Inbred C57BL; D018919:Neovascularization, Physiologic / Q000187:drug effects*; D009416:Nerve Regeneration / Q000187:drug effects / Q000502:physiology*; D055495:Neurogenesis / Q000187:drug effects*; D009457:Neuroglia / Q000166:cytology / Q000187:drug effects / Q000502:physiology; D009474:Neurons / Q000166:cytology / Q000187:drug effects / Q000502:physiology; D020127:Recovery of Function / Q000187:drug effects; D020521:Stroke / Q000188:drug therapy* / Q000503:physiopathology / Q000601:surgery; D016211:Transforming Growth Factor alpha / Q000627:therapeutic use*; D016896:Treatment Outcome
chemical_list: D016211:Transforming Growth Factor alpha; D049452:Green Fluorescent Proteins